Xeltis Presents Promising Data for Xabg, a Revolutionary Conduit
Xeltis has recently shared exciting preliminary data regarding Xabg, its innovative coronary artery bypass conduit (CABG). This groundbreaking development shows significant advancements in safety and patency rates among patients suffering from multi-vessel atherosclerotic coronary artery disease. With the cardiovascular disease prevalence on the rise globally, Xabg offers a beacon of hope for transforming the landscape of CABG surgery.
Encouraging Results from Clinical Trials
The data indicates that Xabg, an advanced biorestorative polymeric conduit, provides an effective solution by allowing continuous blood flow in patients affected by coronary artery disease. Utilizing Xeltis’ proprietary Endogenous Tissue Restoration (ETR) platform, Xabg stands apart due to its unique regenerative properties, which enable patients' living tissues to gradually replace the conduit over time, providing a more sustainable option for heart surgery.
Potential Impact on CABG Procedures
Cabg is recognized as the most prevalent cardiac surgery worldwide, yet it often demands painful vein graft harvesting and presents various complications. Surprisingly, despite the critical nature of this procedure, over 80% still depend on vein grafts with less than satisfactory results. The global CABG market is projected to surge past $20 billion by 2035, driven by the escalating incidence of cardiovascular diseases. Xeltis aims to bridge this gap with its revolutionary Xabg design.
Shaping the Future of Vascular Grafts
Currently, clinical trials across various EU sites affirm the substantial potential Xabg holds in revolutionizing the bypass surgery experience. Early findings suggest the conduit exhibits excellent blood flow, thereby eliminating the necessity for vein harvesting. Moreover, with no off-the-shelf small-diameter grafts showing viable patency rates available, Xabg is positioned to fulfill a considerable clinical demand.
Exceptional Longevity Observed
Earlier trials marked the first instance of an artificial bypass conduit maintaining functionality for a remarkable 24-month duration. Such results reflect the efficacy of Xeltis’ ETR technology in redefining vascular graft possibilities. The safety and patency results mark a crucial milestone, validating both the technology and the company's vision for improving patient outcomes.
Insights from Medical Experts
Dr. Paulo Neves, Chief Medical Officer at Xeltis, expressed great optimism regarding Xabg: "The encouraging safety and patency data is a significant breakthrough for Xeltis. We look forward to further patient engagement and treatments that can revolutionize care for those impacted by coronary artery disease." Additionally, Dr. Isaac George, Surgical Director at Columbia University Medical Center, praised the 24-month findings as revolutionary for patient care.
About Xeltis and its Mission
Xeltis is a medtech pioneer committed to crafting transformative implants that promote the natural formation of durable and functional blood vessels. Catering to millions requiring vascular and cardiovascular interventions yearly, Xeltis uses its advanced polymeric implants through its patented ETR platform. The company’s leading product in development, Xabg, coupled with aXess, its restorative vascular conduit, illustrates Xeltis' dedication to addressing pressing medical challenges and enhancing overall patient outcomes.
Headquartered in the Netherlands and the USA, Xeltis is backed by prominent investors who share its vision of innovation in cardiovascular solutions. This collective aim drives Xeltis closer to commercializing its promising products and furthering healthcare advancements.
Frequently Asked Questions
What is Xabg, and what does it do?
Xabg is a coronary artery bypass conduit developed by Xeltis, designed to facilitate improved blood flow in patients with coronary artery disease.
What are the main benefits associated with Xabg?
Xabg aims to improve safety and efficiency in CABG surgeries while reducing the need for vein grafts, thereby minimizing complications.
How does Xabg's technology differ from traditional options?
Xabg leverages advanced biorestorative properties that allow for the replacement of the conduit with the patient's own living tissue over time, unlike conventional grafts.
What are the outcomes from the recent clinical trials?
Preliminary data indicates positive safety and patency results, with Xabg showing excellent blood flow even 24 months after surgery, a first in artificial graft history.
What is Xeltis’ overall mission?
Xeltis focuses on creating innovative medical solutions that foster the natural regeneration of blood vessels, significantly enhancing patient care and health outcomes.
